Trevi Therapeutics, Inc.
TRVI · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Mar 2026
Open the dashboardInfographicSummary
FY2025 key figures
| $ | FY2025 | FY2024 | Change |
|---|---|---|---|
| Revenue | $0K | $0K | |
| Operating income | −$49.3M | −$51.5M | +4.3% |
| Net income | −$42.8M | −$47.9M | +10.7% |
Latest quarter: Q3 2026
Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 9, 2026
| $ | Q3 2026 | Year earlier | Change |
|---|---|---|---|
| Revenue | $0K | $0K | |
| Operating income | −$24.5M | −$13.9M | −76.3% |
| Net income | −$21.5M | −$11.8M | −82.2% |
Q3 2026 dashboardQ3 2026 infographic
Questions
- What was Trevi Therapeutics's revenue in FY2025?
- $0K in FY2025 (Fiscal year ended Dec 31, 2025), no comparable figure vs $0K a year earlier, per its 10-K filed Mar 2026.
- Was Trevi Therapeutics profitable in FY2025?
- No: net income was −$42.8M and operating income −$49.3M in FY2025.
- What was Trevi Therapeutics's revenue in Q3 2026?
- $0K (n/a vs a year earlier), per its Form 10-Q filed Nov 9, 2026.